Genetic Information

Gene & Transcript Details

Gene
BRCA1
Transcript
NM_007294.3 MANE Select
Total Exons
Reference Sequence
NC_000017.10
Alternative Transcripts
IDStatusDetails
NM_007294.4 MANE Select 7088 nt | 114–5705
NM_007294.2 Alternative 7191 nt | 201–5792
NM_007294.3 RefSeq Select 7224 nt | 233–5824

Variant Details

HGVS Notation
NM_007294.3:c.2155A>G
Protein Change
K719E
Location
Exon 10 (Exon 10 of )
10
5'Exon Structure3'
Functional Consequence
Loss of Function
Alternate Identifiers

Clinical & Population Data

Population Frequency

gnomAD
Global Frequency
0.00708 in 100,000
Extremely Rare
ACMG Criteria Applied PM2
This variant is absent or extremely rare in population databases (PM2 criteria applies).

ClinVar

Open
Classification
Uncertain Significance (VUS)
3 publications
Publications List
PMID: 16267036

Variant summary: BRCA1 c.2155A>G (p.Lys719Glu) results in a conservative amino acid change in the encoded protein sequence. Algorithms developed to predict the effect of missense changes on protein structure and function all suggest that this variant is likely to be tolerated. The variant allele was found at a frequency of 2.7e-05 in 1461928 control chromosomes, predominantly at a frequency of 0.001 within the African or African-American subpopulation in the gnomAD database. Additionally, the variant was reported in 5/2559 African American women (i.e. with an allele frequency of about 0.001), who were older than age 70, and have never had cancer (in the FLOSSIES database), suggesting that the variant might be a benign polymorphism. c.2155A>G, has been reported in the literature in individuals affected with or without a family history of Breast and Ovarian Cancer (Judkins_2005, Pal_2015, Abe_2019). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 30883245, 16267036, 26287763, 15385441). ClinVar contains an entry for this variant (Variation ID: 37452). Based on the evidence outlined above, the variant was classified as likely benign.

PMID: 31911673

Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).

Clinical Statement

"This variant has been reported in ClinVar as Uncertain significance (7 clinical laboratories) and as Likely benign (7 clinical laboratories) and as Likely Benign (1 clinical laboratories) and as Benign by ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel, ClinGen expert panel."

COSMIC Somatic Evidence

Open
COSMIC ID
Recurrence
0 occurrences
PM1 Criteria
Not Applied
COSMIC Database Preview
COSMIC Preview
Accessing full COSMIC database details requires institutional login or subscription.

Functional Impact & Domains

Functional Domain

Hotspot Status
Not a hotspot
Domain Summary
This variant is not located in a mutational hotspot or critical domain.
Related Variants in This Domain
No evidence of other pathogenic variants at this position in gene BRCA1.

Functional Studies & Therapeutic Relevance

Functional Summary

Error in OpenAI Consolidation. OncoKB: BRCA1K719EBRCA1K719ESomaticNCBI Gene:672|Show additional gene information Variant OverviewBRCA1, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.There is no available functional data about the BRCA1 K719E mutation (last reviewed on 04/05/2023), and therefore its biological significance is unknown. JAX-CKB: No results found

Database Previews
OncoKB
OncoKB Preview
JAX-CKB
JAX-CKB Preview

Click on previews to view full database entries. External databases may require institutional access.

Computational Analysis

Pathogenicity Predictions

SpliceAI
Predictor Consensus
Mixed/VUS
PP3 Applied
No
REVEL Score
0.0
Threshold: ≥0.75 = PP3 applied

SpliceAI Scores

Window: ±500bp
Effect Type Score Position
- Acceptor Loss (AL) 0.0 -472 bp
- Donor Loss (DL) 0.0 480 bp
+ Acceptor Gain (AG) 0.0 21 bp
+ Donor Gain (DG) 0.0 144 bp
High impact (≥0.5) Medium impact (0.2-0.49) Low impact (<0.2)

VCEP Guidelines

Applied ACMG/AMP Criteria (VCEP Specific)

Filter Criteria:
PM2

PM2 (Unknown (Pre-LLM))

From pre-LLM assessment (LLM Failed)

BP4

BP4 (Unknown (Pre-LLM))

From pre-LLM assessment (LLM Failed)